Avanos Medical (NYSE:AVNS) Sees Unusually-High Trading Volume – Here’s Why

Avanos Medical, Inc. (NYSE:AVNS) shares saw an uptick in trading volume on Monday . 1,268,474 shares were traded during trading, an increase of 21% from the previous session’s volume of 1,045,180 shares.The stock last traded at $24.6750 and had previously closed at $24.66.

Analyst Ratings Changes

Several brokerages have weighed in on AVNS. Zacks Research raised shares of Avanos Medical from a “strong sell” rating to a “hold” rating in a report on Monday, January 26th. Wall Street Zen lowered shares of Avanos Medical from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. Finally, Weiss Ratings raised shares of Avanos Medical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, April 22nd. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Avanos Medical presently has an average rating of “Reduce”.

Avanos Medical Stock Performance

The company has a market capitalization of $1.15 billion, a price-to-earnings ratio of -15.62 and a beta of 1.58. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.26 and a current ratio of 2.15. The company’s fifty day simple moving average is $16.66 and its two-hundred day simple moving average is $13.73.

Avanos Medical (NYSE:AVNS) last posted its quarterly earnings results on Tuesday, February 24th. The company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.24 by $0.05. Avanos Medical had a negative net margin of 10.40% and a positive return on equity of 5.47%. The business had revenue of $180.90 million during the quarter, compared to analyst estimates of $174.70 million. During the same period in the previous year, the business posted $0.43 EPS. The company’s quarterly revenue was up .7% on a year-over-year basis. Avanos Medical has set its FY 2026 guidance at 0.900-1.100 EPS. Equities research analysts predict that Avanos Medical, Inc. will post 1.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Federated Hermes Inc. boosted its holdings in shares of Avanos Medical by 2.8% in the 4th quarter. Federated Hermes Inc. now owns 25,774 shares of the company’s stock valued at $289,000 after buying an additional 691 shares during the period. Versant Capital Management Inc boosted its holdings in shares of Avanos Medical by 49.7% in the 3rd quarter. Versant Capital Management Inc now owns 2,692 shares of the company’s stock valued at $31,000 after buying an additional 894 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Avanos Medical by 4.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,955 shares of the company’s stock valued at $386,000 after buying an additional 1,121 shares during the period. Azzad Asset Management Inc. ADV boosted its holdings in shares of Avanos Medical by 3.0% in the 3rd quarter. Azzad Asset Management Inc. ADV now owns 43,230 shares of the company’s stock valued at $500,000 after buying an additional 1,240 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its holdings in shares of Avanos Medical by 132.6% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,496 shares of the company’s stock valued at $28,000 after buying an additional 1,423 shares during the period. 95.17% of the stock is owned by institutional investors and hedge funds.

About Avanos Medical

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.